Fresenius Medical Care

Fresenius Medical Care AG & Co. KgaA provides products and services for individuals with renal diseases. The firm develops and manufactures health care products, which includes dialysis and non-dialysis products. It operates through the following segments: North America Segment, EMEA Segment, Asia-Pacific Segment and Latin America Segment. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Fresenius Medical Care AG engages in the provision of products and services for individuals with renal diseases. It operates through the Care Enablement and Care Delivery segments. The Care Enablement segment is involved in the healthcare products business including research and development, manufacturing, supply chain, and commercial operations as well as supporting functions, such as regulatory and quality management. The Care Delivery segment focuses on the health care services for the treatment of CKD, ESRD, and other extracorporeal therapies, including value and risk-based care programs. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.

A. O. Smith

Enbridge

First of Long Island

Federal Realty Investment Trust

Gorman-Rupp

Lowe's

Altria

National Fuel Gas

Polaris

Stanley Black & Decker

Black Friday is a time to gorge on the world's best blue-chip bargains, not just left-over turkey. Today FMS, PII, MO, SWK, LOW, AOS, GRC, NFG, FLIC, ENB, and FRT represent the best Black Friday dividend deals on Wall Street.

11 Black Friday Dividend Aristocrat Deals

Pfizer

Viatris

Three underpriced healthcare stocks provide an opportunity.

3 Stocks With Dividends of 3% or More to Buy on the Dip

Profit estimates are moving in the wrong direction.

Bear of the Day: Fresenius Medical (FMS)

Fresenius Medical's (FMS) third-quarter revenues benefit from strong performance across all the geographic regions and segments. However, rising costs hurt margins.

Fresenius Medical's (FMS) Q3 Earnings and Revenues Top

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS ) Q3 2022 Earnings Conference Call October 31, 2022 10:30 AM ET Company Participants Dominik Heger - Head of Investor Relations Carla Kriwet - Chief Executive Officer & Chair of the Management Board Helen Giza - Deputy Chief Executive Officer, Chief Financial Officer & Chief Transformation Officer Conference Call Participants Tom Jones - Berenberg Graham Doyle - UBS James Vane-Tempest - Jefferies Hassan Al-Wakeel - Barclays Veronika Dubajova - Citi Oliver Metzger - ODDO BHF David Adlington - JPMorgan Robert Davies - Morgan Stanley Falko Friedrichs - Deutsche Bank Szegi Oezener - HSBC Operator Ladies and gentlemen, thank you for standing by. I'm Nathalie your Chorus Call operator.

Fresenius Medical Care AG & Co. KGaA (FMS) Q3 2022 Earnings Call Transcript

Kidney dialysis provider Fresenius Medical Care (FMC) on Sunday revised down its forecast for 2022, expecting net income to decline this year, dragged down by rising labour costs and a slower than expected recovery in North America business.

Fresenius Medical cuts outlook on slower recovery, rising costs

Fresenius Medical Care has been a long-term laggard in its industry, losing over 70% in the past 5 years. The stock has seemingly bottomed and began to retrace on massive buy-side volume while breaking out of one of its most important short-term resistance.

Fresenius: A Contrarian Opportunity Not Seen For 20 Years (Technical Analysis)

Elliott Investment Management has taken a stake in Fresenius SE , seeking to potentially break up the diversified healthcare company, Bloomberg cited people familiar with the matter as saying.

Investor Elliott has taken stake in Germany's Fresenius -Bloomberg

V.F.

The 2022 bear market has been very painful for stock and bond investors but potentially set us up for an epic rally next year. Individual dividend aristocrats are trading at incredible discounts to historical fair value, close to 60% in some cases.

These 2 High-Yield Dividend Aristocrats Are Buffett-Style Table-Pounding Great Buys

HONG KONG--(BUSINESS WIRE)-- #CKDprevention--Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, today signed a memorandum of understanding (MoU) with the National Kidney Foundation (NKF) Malaysia, to work together in promoting kidney health and the prevention of chronic kidney disease amongst children and their families in Malaysia. The organizations will leverage Fresenius Medical Care's international Corporate Social Responsibility (CSR) initiati

Fresenius Medical Care partners with National Kidney Foundation Malaysia in kidney health initiative

Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.

Fresenius Medical (FMS) Robust Product Portfolio Drives Growth

CytoSorbents

Fresenius Medical Care and CytoSorbents have expanded their partnership via a multi-stage collaboration designed to seize new sales opportunities and jointly develop future innovations CytoSorb will be featured on Fresenius Medical Care's critical care platforms for the removal of cytokines, bilirubin, and myoglobin Fresenius Medical Care will be responsible for the specific worldwide marketing and combined promotion of CytoSorb with its critical care products utilizing multiple highly visible and prominent marketing channels and campaigns CytoSorbents' proprietary hemoadsorption CytoSorb therapy expands the dimensions of blood purification of the Fresenius Medical Care critical care product portfolio BAD HOMBURG V.D. HÖHE, GERMANY and PRINCETON, N.J.

CytoSorb® Becomes a Featured Blood Purification Therapy on Fresenius Medical Care Critical Care Platforms

Fresenius Medical's (FMS) second-quarter earnings benefit from strong performance across all the geographic regions and segments. However, rising costs hurt margins.

Fresenius Medical's (FMS) Q2 Earnings Miss, Revenues Top

Fresenius isn't just an undervalued aristocrat, it's a Buffett-style anti-bubble "fat pitch" that could deliver 235% returns in the next five years. Even with the Pandemic-induced downturn, FMS is expected to grow at 12% CAGR through 2027.

Fresenius Medical Care: Best Time In 21 Years To Buy This High-Yield Dividend Aristocrat

Shares of Fresenius Medical Care tumbled 13.7% in premarket trading on Thursday after telling investors to expect lower-than-expected revenue and net income in the second half of the year. The company, which provides kidney dialysis services, cited concerns about wage inflation and staff shortages in North America, higher inflation, and supply-chain disruptions.

Fresenius now expects lower revenue, earnings in the second half, citing wage inflation and staff shortages in North America

German healthcare group Fresenius SE cut its full-year earnings outlook due to cost inflation at its kidney dialysis subsidiary Fresenius Medical Care (FMC), it said late on Wednesday.

Fresenius cuts FY outlook on higher costs at dialysis business

Black Hills

Clorox

Medtronic

MDU Resources Group

Novartis

Northwest Natural Gas

Philip Morris

Fears of a recession are mounting, with BAC and Deutsche Bank now forecasting a mild downturn in 2023. A recession could even begin by December 2022. Even without a recession Morgan Stanley is confident stocks have 10% lower to fall. If we get a mild recession, stocks could fall 25% more and in a severe recession, 35%.

11 High-Yield Dividend Aristocrats Perfect For The Coming Recession

The heavy selling pressure might have exhausted for Fresenius (FMS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

After Plunging 11.8% in 4 Weeks, Here's Why the Trend Might Reverse for Fresenius (FMS)

Here's Why You Should Retain Fresenius Medical (FMS) Stock Now

Allianz SE

British American Tobacco

Legal & General Group PLC

Manulife Financial

Magna International

Muenchener Rueckversicherungs-Gesellschaft AG in Muenchen

Siemens AG

Sanofi

Toronto-Dominion Bank

The US stock market has delivered 6.8% inflation-adjusted annual returns for 206 years, an incredible 768,561X real return since 1816. But there are almost 700,000 publicly traded companies worldwide, many of which can help you retire safely and in splendor.

12 High-Yield Blue-Chip Bargains To Retire In Safety And Splendor

The Department of Justice of the U.S. government files a civil complaint against Fresenius (FMS), accusing it of defrauding Medicare and other healthcare programs by billing for unnecessary procedures.

Fresenius (FMS) Faces Fraud Accusation From US Government

The Renal Research Institute will include the Highmark digital assessment suite into its clinical research of people receiving in-center hemodialysis treatment. TORONTO, ON / ACCESSWIRE / June 20, 2022 / Highmark Interactive Inc. (TSXV:HMRK), a global leader in digital health technologies, announces plans for a collaboration with the Renal Research Institute (RRI), a wholly owned subsidiary of Fresenius Medical Care (NYSE:FMS).

Highmark Interactive Inc. Announces Collaboration with Renal Research Institute to Identify Potential Biomarkers of Brain Injury in Hemodialysis Patients

We'll take a look at Fresenius in order to determine if the company still represents a good investment opportunity. Given a recent share price weakness, it's not strange that some investors are wondering whether it's still investable.

Fresenius: Revisiting The Thesis - Still A Buy

Essex Property Trust

Roche Holding AG

Target

This bear market is the 2nd worst start to the year in US stock market history. And cracks are beginning to form in credit markets that could potentially send stocks falling even lower in the coming months.

My, Oh, My 11 Incredible High-Yield Dividend Aristocrat Bear Market Buys

HONG KONG--(BUSINESS WIRE)-- #healthcare--Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, today announced its global ‘United in Care' campaign that celebrates the diversity, unity and positive impact of its nurses and clinical teams across Asia Pacific, Europe, the Middle East and Africa, North America and Latin America. The campaign dovetails with the organization's current transformation to a new global operating model – enabling it to keep

Fresenius Medical Care Celebrates Diversity and Unity of a Global Nurse Workforce

News for Fresenius Medical Care Stock (FMS)